Forest Laboratories, Inc. Company Profile

Forest Laboratories, Inc.

909 Third Avenue
New York, NY 10022-4731
United States
Tel: 1/212/421-7850
URL: http://www.frx.com
Primary Symbol & Exchange:
FRX - Common Stock - New York Stock Exchange
Industry:
Pharmaceutical
+  SIC Industry Code:
+  NAICS Industry Code:
Mergers & Acquisitions:
Forest Laboratories, Inc. Mergers and Acquisitions
Thomson Financial Business Description:
The Group's principal activities are to develop, manufacture and sell ethical drug products, which require physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. The products consist of ethical drug specialties marketed to physicians by the Group's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare, Forest Ethicare and Forest Specialty Sales. The products of the Group include Lexapro, SSRI for the treatment of major depression and GAD; Namenda, NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, beta-blocker for the treatment of hypertension; and Savella, the newest product, a dual reuptake inhibitor for the treatment of fibromyalgia. The major customers of the Group are McKesson Drug Company, Cardinal Health Inc and AmerisourceBergen Corporation. The Group operates in the United States, the United Kingdom, Ireland and Netherlands.
Alacra Alerts: Forest Laboratories, Inc. RSS Feed  Subscribe with My Yahoo!
Receive alerts on the latest reports on Forest Laboratories, Inc.

Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.

Premium Content Results:







Search for more premium content on Forest Laboratories, Inc.